As AbbVie Prepares To Launch, Some Wind Gets Knocked Out Of Its Sails
Executive Summary
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.